Announcements

Director David W. Gibbs filed a statement of changes in beneficial ownership with the SEC on November 9, 2026, disclosing the acquisition of 278 restricted stock units of Amgen Inc. common stock on November 6, 2026.

Michael G. Combs, CEO and President of CorVel Corp, filed a Form 4 on November 9, 2026, reporting multiple stock option exercises and related share disposals that occurred on November 6, 2026.

CorVel Corp Vice President of Accounting Jennifer Yoss filed a Form 4 on November 9, 2026, disclosing the acquisition of 2,200 non-qualified stock options in CorVel Corp (NASDAQ:CRVL) on November 5, 2026.

Director Charles M. Holley filed a Form 4 with the SEC on November 6, 2026, disclosing the acquisition of 184.614 shares of Amgen Inc. common stock through a restricted stock unit grant at no cost.

Ned N. Fleming III, a director and 10% owner of Construction Partners, Inc. (NASDAQ:ROAD), filed a Form 4 on November 9, 2026, disclosing a privately negotiated purchase of 250 shares of Class B common stock at $88.33 per share on November 9, 2026.

Director Omar Ishrak filed a Form 4 with the SEC on November 7, 2026, reporting the acquisition of 152.0351 shares of Amgen Inc. common stock on November 6, 2026, through a vested Restricted Stock Unit grant at no cost.

ADAR1 Capital Management, LLC and Daniel Schneeberger filed a Form 4 on November 9, 2026, disclosing a purchase of 2,640 common shares of InMed Pharmaceuticals Inc. (now Mentari Therapeutics, Inc.) on November 5, 2026, at a weighted average price of $13.0953 per share.